1. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008; 93:2737–2745. PMID:
18270261.
Article
2. Vermeulen A, Kaufman JM. Ageing of the hypothalamo-pituitary-testicular axis in men. Horm Res. 1995; 43:25–28. PMID:
7721258.
3. Hall SA, Araujo AB, Esche GR, Williams RE, Clark RV, Travison TG, et al. Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey. Arch Intern Med. 2008; 168:1070–1076. PMID:
18504335.
4. Bailey RL, Gahche JJ, Thomas PR, Dwyer JT. Why US children use dietary supplements. Pediatr Res. 2013; 74:737–741. PMID:
24002333.
Article
5. Dickinson A, Blatman J, El-Dash N, Franco JC. Consumer usage and reasons for using dietary supplements: report of a series of surveys. J Am Coll Nutr. 2014; 33:176–182. PMID:
24724775.
Article
6. Aaberg RA, Sauer MV, Sikka S, Rajfer J. Effects of extracellular ionized calcium, diltiazem and cAMP on motility of human spermatozoa. J Urol. 1989; 141:1221–1224. PMID:
2540352.
Article
7. Tahvilzadeh M, Hajimahmoodi M, Toliyat T, Karimi M, Rahimi R. An evidence-based approach to medicinal plants for the treatment of sperm abnormalities in traditional Persian medicine. Andrologia. 2016; 48:860–879. PMID:
27681644.
Article
11. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018; 200:423–432. PMID:
29601923.
Article
12. Sehn E, Mozak C, Yuksel N, Sadowski CA. An analysis of online content related to testosterone supplementation. Aging Male. 2019; 22:141–149. PMID:
29921150.
Article
13. Nguyen SM, Ko Ko N, Sattar AS, Gucuk Ipek E, Ali S. Pulmonary embolism secondary to testosterone-enhancing herbal supplement use. Cureus. 2017; 9:e1545. PMID:
29018642.
Article
14. US Food and Drug Administration (FDA). FDA drug safety communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use [Internet]. Silver Spring (MD): FDA;2018. cited 2019 Feb 28. Available from:
https://www.fda.gov/Drugs/DrugSafety/ucm436259.htm.
15. Engelhardt PF, Riedl CR. Effects of one-year treatment with isoflavone extract from red clover on prostate, liver function, sexual function, and quality of life in men with elevated PSA levels and negative prostate biopsy findings. Urology. 2008; 71:185–190. discussion 190. PMID:
18308079.
Article
16. Fosmire GJ. Zinc toxicity. Am J Clin Nutr. 1990; 51:225–227. PMID:
2407097.
Article